Clinical Trial

An Exploratory Clinical Study of Dalpiciclib an'd Letrozole Combined With Anlotinib Neoadjuvant Therapy in Stage II-III Postmenopausal HR+/HER2- Early Breast Cancer

Name: An Exploratory Clinical Study of Dalpiciclib an'd Letrozole Combined With Anlotinib Neoadjuvant Therapy in Stage II-III Postmenopausal HR+/HER2- Early Breast Cancer — clinical trial record (NCT06605690)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting

View on ClinicalTrials.gov →

Record status

This record was last updated September 20, 2024 (before its estimated August 31, 2025 completion). Its status may not reflect the trial's current state.

Summary

This is a single-arm, open-label, exploratory clinical study

Trial Details

NCT Number	NCT06605690
Lead Sponsor	Liu Shu
Conditions	Breast Cancer
Enrollment	30 participants
Start Date	2024-10-31
Primary Completion	2025-08-31 (estimated)
Study Completion	2026-08-31 (estimated)
Updated on ClinicalTrials.gov	2024-09-20